<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02244944</url>
  </required_header>
  <id_info>
    <org_study_id>13-0972-F1V</org_study_id>
    <nct_id>NCT02244944</nct_id>
  </id_info>
  <brief_title>Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD</brief_title>
  <official_title>The Effect of Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gregory Graf, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to gather information on the combination Zetia® (Ezetimibe)
      and Urso Forte® with respect to sterol balance and their effects on biomarkers of liver
      function in subjects with nonalcoholic fatty liver disease (NAFLD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted as a prospective open label trial with pre- and post-treatment
      measures for all dependent variables. This trial will enroll subjects with a clinical
      diagnosis of nonalcoholic fatty liver disease (NAFLD) by magnetic resonance imaging (MRI),
      computed tomography (CT) or ultrasound, including those diagnosed with nonalcoholic
      steatohepatitis (NASH). Subjects will be consented, blood collected and a MRI conducted on
      the first visit. Patients will be advised on the proper use of the study drug and given the
      first three month's supply of the study drug to take home with them. For the remaining three
      months, study drug will be delivered by US mail along with return packaging for the prior
      three month's study medication in order to monitor compliance. Patients will be called
      routinely to encourage compliance, retention, and monitor side effects or adverse events.
      After six months of study drug administration, subjects will return for a follow-up visit.
      Blood will be drawn, an MRI will be obtained and a post-study questionnaire will be
      administered.

      Duration of Patient Enrollment: 6 months Duration of Study: 18 months
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Failure to recruit
  </why_stopped>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Serum Alanine Transaminase (ALT)</measure>
    <time_frame>6 months</time_frame>
    <description>Determine if Ezetimibe-Ursodiol combination therapy improves liver function tests (ALT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increase in Plasma Lathosterol</measure>
    <time_frame>6 months</time_frame>
    <description>Determine if Ezetimibe-Ursodiol combination therapy promotes a net-negative sterol balance as evidenced by an increase in the cholesterol synthesis intermediate, lathosterol, in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in Hepatic Fat Fraction</measure>
    <time_frame>6 months</time_frame>
    <description>Determine if Ezetimibe-Ursodiol combination therapy reduces total fat in the liver as assessed by MRI</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Nonalcoholic Fatty Liver Disease (NAFLD)</condition>
  <arm_group>
    <arm_group_label>EZ-URSO Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ursodiol (URSO Forte) 13-15 mg per kg (250-500 mg b.i.d. or t.i.d depending on body weight) combined with Ezetimibe (Zetia) 10 mg o.p.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EZ-Urso combination therapy</intervention_name>
    <description>Ursodiol 13-15 mg per kg per day combined with Ezetimibe (Zetia) 10 mg per day</description>
    <arm_group_label>EZ-URSO Combination Therapy</arm_group_label>
    <other_name>Ezetimibe (Zetia)</other_name>
    <other_name>Ursoldiol (URSO Forte)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Steatosis

          -  ALT &gt;1.5 times normal

          -  ALT/AST ratio &gt;1.0

          -  Normal Kidney Function

        Exclusion Criteria:

          -  Normal ALT within last 6 months

          -  Advanced fibrosis based on 1) biopsy, if available (Stage 3 or 4 NAFLD), 2) imaging,
             or 3) lab (platelet count &lt;150,000)

          -  Daily alcohol use above 20 g/day for women and 30 g/day for men

          -  Prescription use of ursodiol, ezetimibe, vitamin E, fish oils, thiazolidinediones,
             insulin, sulfonylureas, HMG-CoA reductase inhibitors

          -  Weight loss greater than 15% in past 12 months

          -  Pregnant or breastfeeding

          -  Body Mass index greater than 50

          -  Largest body circumference greater than 160 cm

          -  Claustrophobia

          -  Allergy to ezetimibe or ursodiol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Graf, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kentucky Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2014</study_first_submitted>
  <study_first_submitted_qc>September 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2014</study_first_posted>
  <results_first_submitted>September 20, 2017</results_first_submitted>
  <results_first_submitted_qc>January 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 7, 2018</results_first_posted>
  <last_update_submitted>January 11, 2018</last_update_submitted>
  <last_update_submitted_qc>January 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Gregory Graf, PhD</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>nonalcoholic fatty liver disease</keyword>
  <keyword>NAFLD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>EZ-URSO Combination Therapy</title>
          <description>Ursodiol (URSO Forte) 13-15 mg per kg (250-500 mg b.i.d. or t.i.d depending on body weight) combined with Ezetimibe (Zetia) 10 mg o.p.d.
EZ-Urso combination therapy: Ursodiol 13-15 mg per kg per day combined with Ezetimibe (Zetia) 10 mg per day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Terminated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>EZ-URSO Combination Therapy</title>
          <description>Ursodiol (URSO Forte) 13-15 mg per kg (250-500 mg b.i.d. or t.i.d depending on body weight) combined with Ezetimibe (Zetia) 10 mg o.p.d.
EZ-Urso combination therapy: Ursodiol 13-15 mg per kg per day combined with Ezetimibe (Zetia) 10 mg per day</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.5" lower_limit="33" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reduction in Serum Alanine Transaminase (ALT)</title>
        <description>Determine if Ezetimibe-Ursodiol combination therapy improves liver function tests (ALT)</description>
        <time_frame>6 months</time_frame>
        <population>The trial was terminated early. No data was collected to analyze the primary outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>EZ-URSO Combination Therapy</title>
            <description>Ursodiol (URSO Forte) 13-15 mg per kg (250-500 mg b.i.d. or t.i.d depending on body weight) combined with Ezetimibe (Zetia) 10 mg o.p.d.
EZ-Urso combination therapy: Ursodiol 13-15 mg per kg per day combined with Ezetimibe (Zetia) 10 mg per day</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction in Serum Alanine Transaminase (ALT)</title>
          <description>Determine if Ezetimibe-Ursodiol combination therapy improves liver function tests (ALT)</description>
          <population>The trial was terminated early. No data was collected to analyze the primary outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Increase in Plasma Lathosterol</title>
        <description>Determine if Ezetimibe-Ursodiol combination therapy promotes a net-negative sterol balance as evidenced by an increase in the cholesterol synthesis intermediate, lathosterol, in plasma.</description>
        <time_frame>6 months</time_frame>
        <population>The trial was terminated early. No data was collected to analyze the secondary outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>EZ-URSO Combination Therapy</title>
            <description>Ursodiol (URSO Forte) 13-15 mg per kg (250-500 mg b.i.d. or t.i.d depending on body weight) combined with Ezetimibe (Zetia) 10 mg o.p.d.
EZ-Urso combination therapy: Ursodiol 13-15 mg per kg per day combined with Ezetimibe (Zetia) 10 mg per day</description>
          </group>
        </group_list>
        <measure>
          <title>Increase in Plasma Lathosterol</title>
          <description>Determine if Ezetimibe-Ursodiol combination therapy promotes a net-negative sterol balance as evidenced by an increase in the cholesterol synthesis intermediate, lathosterol, in plasma.</description>
          <population>The trial was terminated early. No data was collected to analyze the secondary outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction in Hepatic Fat Fraction</title>
        <description>Determine if Ezetimibe-Ursodiol combination therapy reduces total fat in the liver as assessed by MRI</description>
        <time_frame>6 months</time_frame>
        <population>The trial was terminated early. No data was collected to analyze the primary outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>EZ-URSO Combination Therapy</title>
            <description>Ursodiol (URSO Forte) 13-15 mg per kg (250-500 mg b.i.d. or t.i.d depending on body weight) combined with Ezetimibe (Zetia) 10 mg o.p.d.
EZ-Urso combination therapy: Ursodiol 13-15 mg per kg per day combined with Ezetimibe (Zetia) 10 mg per day</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction in Hepatic Fat Fraction</title>
          <description>Determine if Ezetimibe-Ursodiol combination therapy reduces total fat in the liver as assessed by MRI</description>
          <population>The trial was terminated early. No data was collected to analyze the primary outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>EZ-URSO Combination Therapy</title>
          <description>Ursodiol (URSO Forte) 13-15 mg per kg (250-500 mg b.i.d. or t.i.d depending on body weight) combined with Ezetimibe (Zetia) 10 mg o.p.d.
EZ-Urso combination therapy: Ursodiol 13-15 mg per kg per day combined with Ezetimibe (Zetia) 10 mg per day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gregory Graf</name_or_title>
      <organization>University of Kentucky</organization>
      <phone>8592574749</phone>
      <email>Gregory.Graf@uky.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

